![Zynerba Pharmaceuticals, Inc. logo](/logos/ZYNE.webp)
Zynerba Pharmaceuticals, Inc.
NASDAQ:ZYNE
Overview | Financials
Company Name | Zynerba Pharmaceuticals, Inc. |
Symbol | ZYNE |
Currency | USD |
Price | 1.3 |
Market Cap | 70,121,220 |
Dividend Yield | 0% |
52-week-range | 0.25 - 1.4 |
Industry | Drug Manufacturers—Specialty & Generic |
Sector | Healthcare |
CEO | Mr. Armando Anido MBA |
Website | https://www.zynerba.com |
An error occurred while fetching data.
About Zynerba Pharmaceuticals, Inc.
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD